Globus Medical (GMED) Expected to Announce Earnings on Thursday

Globus Medical (NYSE:GMED) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $1.12 per share and revenue of $782.8540 million for the quarter. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.68 EPS. On average, analysts expect Globus Medical to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Globus Medical Price Performance

Globus Medical stock opened at $81.32 on Thursday. The firm has a market capitalization of $11.04 billion, a PE ratio of 18.91, a P/E/G ratio of 1.66 and a beta of 0.95. The company’s 50-day moving average is $79.73 and its 200-day moving average is $85.76. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 18.38% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

A number of institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC grew its holdings in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares in the last quarter. Parallel Advisors LLC grew its holdings in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares in the last quarter. Headlands Technologies LLC increased its position in Globus Medical by 485.4% during the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after buying an additional 631 shares during the period. Finally, Hollencrest Capital Management acquired a new stake in shares of Globus Medical during the fourth quarter worth $51,000. Institutional investors own 95.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GMED shares. Needham & Company LLC raised their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. UBS Group assumed coverage on Globus Medical in a research note on Tuesday. They issued a “neutral” rating and a $82.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Monday, July 13th. Finally, Royal Bank Of Canada reduced their target price on Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $102.08.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.